Virtual reality visual field testing for people with open-angle glaucoma
Evaluation of the Accuracy and Reproducibility of Visual Field Testing Using a Virtual Reality Head-Mounted Device for Patients With Early, Moderate, and Advanced Glaucoma
This will test whether a virtual reality visual field test can match the standard Humphrey Field Analyzer for people with open‑angle glaucoma.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nova Scotia Health Authority Academic / other |
| Locations | 1 site (Halifax, Nova Scotia) |
| Trial ID | NCT07063537 on ClinicalTrials.gov |
What this trial studies
This interventional study compares a Pico-based virtual reality (VR) visual field system directly with the Zeiss Humphrey Field Analyzer by having participants complete both tests in randomized order. Each participant will undergo testing for both eyes during five separate sessions at least 24 hours apart to measure global and pointwise thresholds and reproducibility. The study will examine whether glaucoma stage (early, moderate, advanced) or scotomas affect agreement between devices and will compare reliability indices. Participants will also complete a questionnaire about their experience with each test.
Who should consider this trial
Good fit: Adults over 18 with a diagnosis of primary open‑angle glaucoma who can perform visual field testing and provide informed consent are ideal candidates.
Not a fit: Patients with secondary glaucoma or non‑glaucomatous optic neuropathy, significant media opacity, recent intraocular surgery (other than cataract or minimally invasive glaucoma surgery), or contraindications such as seizure disorder, pacemaker/implantable device, pregnancy, or severe vertigo are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, this could provide a portable, less burdensome option to monitor visual field loss in glaucoma that performs similarly to the current clinical standard.
How similar studies have performed: Prior small studies of VR perimetry have shown promising agreement with standard perimeters, but larger reproducibility data are still limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * \>18 years of age * diagnosis of primary open-angle glaucoma * ability to perform visual field testing * capacity to provide informed consent to research protocol Exclusion Criteria: * diagnosis of secondary glaucoma or non-glaucomatous optic neuropathy * previous intraocular surgery (excluding cataract surgery and minimally invasive glaucoma surgery) * significant media opacity * pregnancy * seizure disorder * cardiac pacemaker/other implantable device * severe vertigo/balance disorder
Where this trial is running
Halifax, Nova Scotia
- Eadie Technologies Inc — Halifax, Nova Scotia, Canada (Recruiting)
Study contacts
- Principal investigator: Brennan Eadie, MD, PhD, FRCSC — Nova Scotia Health
- Study coordinator: Reann Post, BSc
- Email: reann.post@dal.ca
- Phone: 19029560601
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.